TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01736748

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sensor based PA intervention
Description: Children will be equipped with a heart rate monitor, a GPS receiver and an accelerometer for collection of heart rate, mobility and physical activity free-living data during a 7-day period. This will provide a 'spatio-behavioural diagnosis' using a map-based interactive web application. This data will be used to developed a tailored plan to promote physical activity in the child's every day environment.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Traditional PA counseling
Description: Children will be encouraged to enhance their physical activity levels using traditional behavioral approaches.
Study: NCT01910337

Intervention type: DEVICE
Intervention: Use the Polar Cardiac rate meter

Intervention type: DEVICE
Intervention: Use the Polar Cardiac rate meter

Intervention type: DEVICE
Intervention: Use the Polar Cardiac rate meter
Study: NCT01150006

Intervention type: OTHER
Intervention: Cross sectional study
Description: This is not intervention study. The purpose of the study is to examine the relationship between various adipokine levels and PET imaging at the cross section setting
Study: NCT00664287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: niacin (+) laropiprant
Description: Group 1: Patients will receive ER niacin/laropiprant 1 g/20 mg daily. After 4 weeks, ER niacin/laropiprant will be increased to 2 g/40 mg for remainder of study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo (unspecified)
Description: Group 2: Patients will receive 1 placebo tablet daily. After 4 weeks, patients will be advanced to 2 placebo tablets for remainder of the study.
Study: NCT03635983

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NKTR-214
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days
Study: NCT04735107

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: colorectal anastomosis reinforcement and trans-anal drainage
Description: Circular mucosal flap created to cover stapled anastomosis + vacuum sponge drainage
Study: NCT00817141

Intervention type: OTHER
Intervention: Observational study, no intervention
Description: Observation of the complications seen without urinary catheter (which is the habitual protocol in our institution)
Study: NCT01719978

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3.6mL 2% Mepivacaine with 1:100,000 epinephrine
Description: Local anesthetic with vasoconstrictor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 3.6mL 2% Mepivacaine with 1:100,000 epinephrine
Description: Local anesthetic with vasoconstrictor

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lower Third Molar Extraction
Description: Lower Third Molar Extraction with LA + hyaluronidase (or placebo)

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Lower Third Molar Extraction
Description: Lower Third Molar Extraction with LA + hyaluronidase (or placebo)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronidase
Description: 75RTU Hyaluronidase administration concomitant to the local anesthetic
Study: NCT03523845

Intervention type: OTHER
Intervention: Observational intervention to diagnose an early apical peri-implantitis
Description: diagnose an early apical peri-implantitis

Intervention type: OTHER
Intervention: Observational intervention to diagnose an early apical peri-implantitis
Description: diagnose an early apical peri-implantitis
Study: NCT00894517

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Description: OnabotulinumtoxinA (botulinum toxin Type A) 200U injected into the prostate on Day 1.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (saline)
Description: Saline injected into the prostate on Day 1.
Study: NCT00460109

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: denileukin diftitox

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Study: NCT02095340

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Positive Interpretation Bias Training

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Neutral Interpretation Bias Training
Study: NCT03946917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS001
Description: JS001 3 mg/kg, iv drip, d1, d15, q4w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: regorafenib tablet
Description: 80/120/160 mg, po, d1-d21, Q4w.
Study: NCT03860337

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alginate Sausage
Description: Alginate sausage

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alginate Sausage
Description: Alginate sausage

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Sausage
Description: Control Sausage

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Sausage
Description: Control Sausage
Study: NCT00703131

Intervention type: DEVICE
Intervention: Anal Fistula Plug (SurgiSIS AFP)
Description: Anal Fistula Plug
Study: NCT04244799

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral nudges
Description: Behavioral nudges include the following:~1. Colorful pathway overlaid with footprints leading from the toilet to the handwashing station~2. Rotating posters in toilet areas with messages targeting behavioral motivators for handwashing (disgust, social affiliation)~3. Sticker of a pair of eyes placed above the handwashing station~4. Soap dish with an arrow beside it on the sink or counter to remind children to wash their hands with soap

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: National WASH policy
Description: The Philippines' Department of Education National WASH in Schools (WinS) policy promotes correct hygiene and sanitation practices among school children and a clean environment in and around schools and includes initiatives related to infrastructure, knowledge, and behavior change, but does not include other programs with an explicit focus on handwashing promotion.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: National WASH policy
Description: The Philippines' Department of Education National WASH in Schools (WinS) policy promotes correct hygiene and sanitation practices among school children and a clean environment in and around schools and includes initiatives related to infrastructure, knowledge, and behavior change, but does not include other programs with an explicit focus on handwashing promotion.
Study: NCT01719978

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1mL 0.9% saline administration concomitant to the local anesthetic
Study: NCT03400566

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Narrative
Description: Children will be read a story book featuring vegetables for a minimum of 7 times (including twice during the familiarization phase).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Narrative
Description: Children will be read a story book featuring vegetables for a minimum of 7 times (including twice during the familiarization phase).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Narrative
Description: Children will be read a story book featuring vegetables for a minimum of 7 times (including twice during the familiarization phase).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Narrative
Description: Children will be read a story book featuring vegetables for a minimum of 7 times (including twice during the familiarization phase).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Experiential
Description: Children will receive hands on experience with the vegetable. They will get to listen, see, feel, touch and smell the actual vegetable during the two familiarization phases.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experiential
Description: Children will receive hands on experience with the vegetable. They will get to listen, see, feel, touch and smell the actual vegetable during the two familiarization phases.
Study: NCT01820065

Intervention type: PROCEDURE
Intervention: Cataract surgery with IOL implantation
Description: Phacoemulsification with implantation of single piece Acrysof IOL
Study: NCT01723657

Intervention type: DRUG
Group type: OTHER
Intervention: Ara-C
Description: * Intermediate dose during induction phase to remission.~* High dose during consolidation phase in patients with favorable cytogenetics and leukocyte index below 20.

Intervention type: OTHER
Group type: OTHER
Intervention: Autologous peripheral blood stem cell transplantation.
Description: * In patients with favorable cytogenetics with a Leukocyte index above 20.~* Patients with normal karyotype, and one cycle of chemotherapy to achieve complete remission, without adverse molecular and/or minimal residual disease (MRD) characteristics, regardless availability of a matched donor.

Intervention type: OTHER
Group type: OTHER
Intervention: Allogeneic matched related or unrelated donor transplant.
Description: -Patients without favorable/intermediate characteristics.

Intervention type: DRUG
Group type: OTHER
Intervention: G-CSF
Description: * Administration at induction phase to remission, days 0 to 7. G-CSF will not be initiated if the leukocyte count is over 30x10e9/L at diagnosis or will be interrupted if the leukocyte count during treatmen arises 30x10e9/L.~* Administration at consolidation phase, days 4 to 6 (3 doses). G-CSF will be interrupted if the leukocyte count during treatment arises 30x10e9/L.

Intervention type: OTHER
Group type: OTHER
Intervention: CD34+ selection.
Description: -Patients with adverse prognosis with allogeneic peripheral blood stem cell (PBSC)tranplantation, CD34+ cell selection of the inoculum was performed.

Intervention type: OTHER
Group type: OTHER
Intervention: Mylotarg purging before autologous PBSC transplantation
Description: Patients without favorable/intermediate characteristics and without matched related donor.
Study: NCT03881670

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Lotrafilcon B
Description: commercially available contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lotrafilcon B
Description: commercially available contact lens

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: lotrafilcon B with Hydraluxe
Description: commercially available contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lotrafilcon B with Hydraluxe
Description: commercially available contact lens
Study: NCT00381550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triapine
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative study
Study: NCT01931930

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Perilla extract

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Study: NCT00837356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Advate®
Description: Subjects will receive Advate® at a dose of 50 IU/kg body weight in the first session

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: turoctocog alfa
Description: After a washout period of 4 days, subjects will subsequently receive turoctocog alfa (recombinant factor VIII (N8)) at a dose of 50 IU/kg body weight in the second session
Study: NCT04426708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMS5552
Description: single dose of HMS5552 25mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMS5552
Description: single dose of HMS5552 25mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMS5552
Description: single dose of HMS5552 25mg
Study: NCT03523234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neoadjuvant chemotherapy
Description: etoposide with cisplatin/carboplatin, undergoing in prior to the surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radical surgery for stage II and IIIA small cell lung cancer (SCLC)
Description: Lobectomy/total lung resection plus mediastinal lymph node dissection.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: prophylactic cranial irradiation
Description: prophylactic cranial irradiation (PCI) undergoing with adjuvant chemotherapy simultaneously

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: prophylactic cranial irradiation
Description: prophylactic cranial irradiation (PCI) undergoing with adjuvant chemotherapy simultaneously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Chemotherapy
Description: etoposide with cisplatin/carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: etoposide with cisplatin/carboplatin
Study: NCT00891007

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-mBN85B
Description: Low Dose arm, 1x 10E7 TCID50

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-mBN85B
Description: Normal Dose arm, 1x 10E8 TCID50

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rouvax
Description: Standard measles vaccine, approved in South Africa
Study: NCT01180647

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Extended-Release Naltrexone
Description: 380mg IM XR-NTX injection one week prior to release from jail; a second XR-NTX 380mg IM injection is offered 4 weeks later (monthly).

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Motivational Enhancement Counseling
Description: The randomized control arm receives no medication treatment and is offered brief, two-session Motivational Enhancement counseling prior to release from jail.
Study: NCT03384888

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS
Description: Transcranial direct current stimulation Duration: 20 minutes; Intensity: 2 mA (miliamps); Placement of the electrodes: anode over the left M1 and cathode region over the right supraorbital region.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS
Description: Transcranial direct current stimulation Duration: 20 minutes; Intensity: 2 mA (miliamps); Placement of the electrodes: anode over the left M1 and cathode region over the right supraorbital region.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: Sham Transcranial direct current stimulation The procedure is the same as for active tDCS, but the stimulation is non-active / sham.
Study: NCT02715245

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Home-based rehabilitation
Description: Procedure/Surgery: Home-based rehabilitation In the patient's home, the primarily applied treatment has been physical therapy, seeking to achieve the highest possible functionality and gait training. In more than 25% of cases, health education is conducted for families and caregivers. Thus, consistent with the patient's condition and their tolerance to activity and to exercise their self-care independently, rehabilitation interventions are activated that prevent sequelae derived from functional limitations.
Study: NCT00660751

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine
Description: SNRIs

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Duloxetine
Description: SNRIs
Study: NCT02243969

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Flaxseed oil
Description: The flaxseed oil will be provided in vials containing 5 g of oil, and should be taken for twelve weeks during the experimental period twice a day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: high oleic sunflower oil (HOSF)
Description: The HOSF will be provided in vials containing 5 g of oil, and should be taken for twelve weeks during the experimental period twice a day
Study: NCT01044706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Description: 50 mg Oral Tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bicalutamide
Description: 50 mg Oral Tablet
Study: NCT03539146

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary fiber
Description: Intake of yogurt containing cascara with 0%, 3%, 7%,13% dietary fiber in a crossover design.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control yogurt
Description: Control yogurt
Study: NCT01481181

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc enriched water
Description: 3mg zinc/L of purified water from a filter installed in the households
Study: NCT00847730

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: V.A.C. Negative Pressure Wound Therapy System
Description: This is a non-invasive wound treatment system that uses controlled, localized negative pressure to create an environment that promotes wound healing in chronic and acute wounds
Study: NCT03317392

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tissue biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tissue biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT04084366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OBI-999
Description: For the dose-escalation phase, OBI-999 will be administered on Day 1 of each 21-day cycle, for up to 35 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OBI-999
Description: For the dose-expansion phase, OBI-999 will be administered on Day 1 of each 21-day cycle, for up to 35 cycles.
Study: NCT01333579

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive transcranial magnetic stimulation
Description: Repetitive transcranial magnetic stimulation, frequency of 1Hz, once a day for ten days.
Study: NCT03277950

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality with feedback
Description: Individuals with stroke play game with correction of movement.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Virtual reality without feedback
Description: Individuals with stroke play game without correction of movement.

Intervention type: OTHER
Group type: OTHER
Intervention: Healthy
Description: Healthy do not play game
Study: NCT00323622

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' candidate Plasmodium falciparum malaria vaccine 257049
Description: IM injection in the deltoid muscle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' candidate Plasmodium falciparum malaria vaccine 257049
Description: IM injection in the deltoid muscle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' candidate Plasmodium falciparum malaria vaccine 257049
Description: IM injection in the deltoid muscle
Study: NCT03317392

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study: NCT00323622

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' candidate Plasmodium falciparum malaria vaccine 257049
Description: IM injection in the deltoid muscle
Study: NCT03317392

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT01120093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aclidinium bromide 100 μg bid
Description: Aclidinium bromide 100 μg twice-daily via inhalation by Eklira Genuair® inhaler: 1 puff in the morning and evening for 7 days
Study: NCT03317392

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radium Ra 223 Dichloride
Description: Given IV
Study: NCT01120093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aclidinium bromide 200 μg bid
Description: Aclidinium bromide 200 μg twice-daily via inhalation by Eklira Genuair® inhaler: 1 puff in the morning and evening for 7 days
Study: NCT03317392

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radium Ra 223 Dichloride
Description: Given IV
Study: NCT03697213

Intervention type: OTHER
Intervention: Online study
Description: 20 hypothetical patient summaries
Study: NCT02596035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Study: NCT02376036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGD010
Description: MGD010 is a CD32B x CD79B bi-specific antibody-based molecular construct referred to as a Dual Affinity Re-Targeting (DART) molecule. MGD010 will be administered as a single agent.
Study: NCT01120093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aclidininum bromide 400 μg bid
Description: Aclidinium bromide 400 μg twice-daily via inhalation by Eklira Genuair® inhaler: 1 puff in the morning and evening for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo via inhalation in the morning and evening for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol 12 μg bid
Description: Formoterol 12 μg twice-daily via inhalation by Aerolizer® dry powder inhaler: 1 puff in the morning and evening for 7 days